A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results